Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 198543, 6 pages
http://dx.doi.org/10.1155/2015/198543
Clinical Study

Salvage Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome

1Department of Urology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
2Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, 9000 Ghent, Belgium
3Department of Nuclear Medicine, Ghent University Hospital, 9000 Ghent, Belgium
4Department of Radiology, Ghent University Hospital, 9000 Ghent, Belgium

Received 11 July 2014; Accepted 2 November 2014

Academic Editor: Achilles Ploumidis

Copyright © 2015 Tom Claeys et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013,” European Urology, vol. 65, no. 1, pp. 124–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy,” Journal of the American Medical Association, vol. 294, no. 4, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Boorjian, R. H. Thompson, M. K. Tollefson et al., “Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence,” European Urology, vol. 59, no. 6, pp. 893–899, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. N. Simmons, A. J. Stephenson, and E. A. Klein, “Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy,” European Urology, vol. 51, no. 5, pp. 1175–1184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Evangelista, F. Zattoni, A. Guttilla, G. Saladini, P. M. Colletti, and D. Rubello, “Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis,” Clinical Nuclear Medicine, vol. 38, no. 5, pp. 305–314, 2013. View at Google Scholar · View at Scopus
  6. P. Ost, K. Decaestecker, B. Lambert et al., “Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer,” The Prostate, vol. 74, no. 3, pp. 297–305, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. G. R. Pond, G. Sonpavde, R. de Wit, M. A. Eisenberger, I. F. Tannock, and A. J. Armstrong, “The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer,” European Urology, vol. 65, no. 1, pp. 3–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Singh, W. S. Yi, R. A. Brasacchio et al., “Is there a favorable subset of patients with prostate cancer who develop oligometastases?” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 1, pp. 3–10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. T. Schweizer, X. C. Zhou, H. Wang et al., “Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy,” Annals of Oncology, vol. 24, no. 11, Article ID mdt335, pp. 2881–2886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. L. G. Taylor, S. E. Canfield, and X. L. Du, “Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer,” Cancer, vol. 115, no. 11, pp. 2388–2399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Berkovic, G. de Meerleer, L. Delrue et al., “Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy,” Clinical Genitourinary Cancer, vol. 11, no. 1, pp. 27–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Rigatti, N. Suardi, A. Briganti et al., “Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography,” European Urology, vol. 60, no. 5, pp. 935–943, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Jilg, H. C. Rischke, S. N. Reske et al., “Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer,” Journal of Urology, vol. 188, no. 6, pp. 2190–2197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Winter, J. Uphoff, R.-P. Henke, and F. Wawroschek, “First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy,” Urologia Internationalis, vol. 84, no. 4, pp. 418–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Rinnab, F. M. Mottaghy, J. Simon et al., “[11C]choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study,” Urologia Internationalis, vol. 81, no. 2, pp. 191–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Suardi, G. Gandaglia, A. Gallina et al., “Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years,” European Urology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Abdollah, R. J. Karnes, N. Suardi et al., “Predicting survival of patients with node-positive prostate cancer following multimodal treatment,” European Urology, vol. 65, no. 3, pp. 554–562, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Abdollah, A. Briganti, F. Montorsi et al., “Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy,” European Urology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Heidenreich, “Guidelines and counselling for treatment options in the management of prostate cancer,” Recent Results in Cancer Research, vol. 175, pp. 131–162, 2007. View at Google Scholar · View at Scopus
  20. D. Dindo, N. Demartines, and P.-A. Clavien, “Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey,” Annals of Surgery, vol. 240, no. 2, pp. 205–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Busch, S. Hinz, C. Kempkensteffen et al., “Selective lymph node dissection for castration-resistant prostate cancer,” Urologia Internationalis, vol. 88, no. 4, pp. 441–446, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Van Praet, K. Decaestecker, V. Fonteyne et al., “Contemporary minimally-invasive extended pelvic lymph node dissection for prostate cancer before curative radiotherapy: prospective standardized analysis of complications,” International Journal of Urology, vol. 21, no. 11, pp. 1138–1143, 2014. View at Publisher · View at Google Scholar
  23. K. Decaestecker, G. de Meerleer, B. Lambert et al., “Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence,” Radiation Oncology, vol. 9, article 135, 2014. View at Publisher · View at Google Scholar
  24. T. Martini, R. Mayr, E. Trenti et al., “The role of 11C-choline-PET/CT-guided secondary lymphadenectomy in patients with PSA failure after radical prostatectomy: lessons learned from eight cases,” Advances in Urology, vol. 2012, Article ID 601572, 4 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus